Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CRAIG E HERRMAN

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1750385332
CMS profile
125098
Location
INDIANAPOLIS, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,580.63

86 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,446.14 84
Education $134.49 2

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CRAIG E HERRMAN

NPI 1750385332 · CMS profile ID 125098

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

INDIANAPOLIS, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1750385332?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CRAIG E HERRMAN, NPI 1750385332, CMS profile ID 125098. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1750385332?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). CRAIG E HERRMAN, NPI 1750385332, CMS profile ID 125098. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1750385332?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
CRAIG E HERRMAN, NPI 1750385332, CMS profile ID 125098, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1750385332?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

86 matching records · $1,580.63 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 86 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–86 of 86.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Genentech USA, Inc. $12.5506/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835898763 CMS
BANNER LIFE SCIENCES, LLC $12.6806/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843738189 CMS
Allergan, Inc. $21.7706/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792802331 CMS
Takeda Pharmaceuticals U.S.A., Inc. $25.4805/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819973021 CMS
Novartis Pharmaceuticals Corporation $20.7205/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812717393 CMS
EMD Serono, Inc. $11.1805/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849196061 CMS
Biogen, Inc. $13.7205/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827761819 CMS
GENZYME CORPORATION $20.2305/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843611697 CMS
Biohaven Pharmaceuticals, Inc. $13.2205/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852516203 CMS
Novartis Pharmaceuticals Corporation $18.7605/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812717391 CMS
Allergan, Inc. $14.7205/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792802329 CMS
Novartis Pharmaceuticals Corporation $10.9305/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812717385 CMS
Novartis Pharmaceuticals Corporation $1.4105/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812717389 CMS
UCB, Inc. $27.4605/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807348607 CMS
AbbVie Inc. $20.3805/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794813541 CMS
Allergan, Inc. $13.0505/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792802327 CMS
PFIZER INC. $12.2204/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833347821 CMS
Novartis Pharmaceuticals Corporation $10.8204/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812717383 CMS
Genentech USA, Inc. $16.7404/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835898777 CMS
Novartis Pharmaceuticals Corporation $18.7204/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812717387 CMS
Janssen Pharmaceuticals, Inc $17.7504/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788639809 CMS
Novartis Pharmaceuticals Corporation $4.5704/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812717379 CMS
Novartis Pharmaceuticals Corporation $18.9203/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812717381 CMS
Alexion Pharmaceuticals, Inc. $12.6903/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783124469 CMS
ACADIA Pharmaceuticals Inc $11.5803/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838001929 CMS
Novartis Pharmaceuticals Corporation $12.0303/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812717377 CMS
SANOFI-AVENTIS U.S. LLC $17.2003/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843611691 CMS
Novartis Pharmaceuticals Corporation $19.7403/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812717375 CMS
EMD Serono, Inc. $13.3103/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849168539 CMS
Merz Pharmaceuticals, LLC $19.6303/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845432105 CMS
Amgen Inc. $12.0102/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825233615 CMS
Genentech USA, Inc. $13.3302/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835898775 CMS
UCB, Inc. $22.5102/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807312523 CMS
Novartis Pharmaceuticals Corporation $7.0402/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812717373 CMS
EMD Serono, Inc. $11.7701/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849160601 CMS
GENZYME CORPORATION $17.9601/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843611663 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,136.41 163
PY2020 $1,680.79 82
PY2021 $1,580.63 86
PY2022 $1,837.95 103
PY2023 $2,908.09 155
PY2024 $3,000.84 149
PY2025 $3,717.81 160

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,560,056.68 46
PY2024 Principal investigator $1,219,457.23 47
PY2023 Principal investigator $1,362,470.87 37
PY2022 Principal investigator $1,474,908.86 18
PY2021 Recipient $703.81 1
PY2021 Principal investigator $1,119,808.74 43
PY2020 Principal investigator $588,547.59 32
PY2019 Principal investigator $417,966.31 57

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

46 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 TG Therapeutics, Inc. $3,800.00 12/12/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200103
Principal investigator 1 TG Therapeutics, Inc. $7,099.45 12/09/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200101
Principal investigator 1 Novartis Pharmaceuticals Corporation $183,467.18 12/01/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190307325
Principal investigator 1 TG Therapeutics, Inc. $4,803.48 11/18/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200089
Principal investigator 1 TG Therapeutics, Inc. $34,418.30 11/01/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200099
Principal investigator 1 Genentech, Inc. $13,771.00 10/28/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY PC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211619185
Principal investigator 1 Genentech, Inc. $3,323.00 10/28/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY PC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211619189
Principal investigator 1 Genentech, Inc. $7,438.50 10/17/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY PC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211619154
Principal investigator 1 TG Therapeutics, Inc. $10,459.60 09/30/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200069
Principal investigator 1 TG Therapeutics, Inc. $5,465.55 09/30/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200075
Principal investigator 1 Genentech, Inc. $379.71 09/18/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY PC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211619146
Principal investigator 1 Genentech, Inc. $228.00 09/18/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY PC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211619150
Principal investigator 1 TG Therapeutics, Inc. $1,868.02 09/02/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200085
Principal investigator 1 TG Therapeutics, Inc. $59,498.45 08/31/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200067
Principal investigator 1 Novartis Pharmaceuticals Corporation $16,746.08 08/21/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY, PC
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190305797
Principal investigator 1 TG Therapeutics, Inc. $8,005.80 08/18/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200083
Principal investigator 1 TG Therapeutics, Inc. $64,935.00 08/07/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200073
Principal investigator 1 TG Therapeutics, Inc. $1,868.02 08/06/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200081
Principal investigator 1 TG Therapeutics, Inc. $46,187.05 07/31/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200065
Principal investigator 1 Genentech, Inc. $12,349.00 07/21/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY PC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211619180
Principal investigator 1 Genentech, Inc. $174.91 07/15/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY PC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211619138
Principal investigator 1 Genentech, Inc. $703.49 07/15/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY PC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211619141
Principal investigator 1 TG Therapeutics, Inc. $3,736.04 07/08/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200079
Principal investigator 1 TG Therapeutics, Inc. $80,966.45 07/01/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200071
Principal investigator 1 TG Therapeutics, Inc. $3,736.04 06/30/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200057
Principal investigator 1 Genentech, Inc. $2,357.00 06/02/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY PC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211619158
Principal investigator 1 TG Therapeutics, Inc. $2,500.00 06/01/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200039
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,267.72 05/22/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY, PC
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190305799
Principal investigator 1 Genentech, Inc. $36,614.00 05/09/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY PC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211619174
Principal investigator 1 TG Therapeutics, Inc. $8,272.66 05/05/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200055
Principal investigator 1 Genentech, Inc. $398.89 04/24/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY PC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211619127
Principal investigator 1 Genentech, Inc. $775.00 04/24/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY PC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211619135
Principal investigator 1 Genentech, Inc. $20,505.60 04/17/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY PC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211619131
Principal investigator 1 TG Therapeutics, Inc. $8,005.80 04/02/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200053
Principal investigator 1 TG Therapeutics, Inc. $7,200.00 03/30/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200037
Principal investigator 1 Novartis Pharmaceuticals Corporation $97,275.19 02/28/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190307627
Principal investigator 1 TG Therapeutics, Inc. $8,050.00 02/28/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200035
Principal investigator 1 Genentech, Inc. $9,026.00 02/14/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY PC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211619170
Principal investigator 1 Genentech, Inc. $3,570.00 02/13/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY PC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211619166
Principal investigator 1 TG Therapeutics, Inc. $6,671.50 02/03/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200047
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,296.67 01/31/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190307625
Principal investigator 1 TG Therapeutics, Inc. $21,100.00 01/31/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200033
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,760.00 01/28/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY, PC
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190305795
Principal investigator 1 Genentech, Inc. $8,000.00 01/17/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY PC
Ocrevus Subcutaneous Study for Safety and Tolerability No dispute reported 06/30/2026 1211619193
Principal investigator 1 TG Therapeutics, Inc. $8,005.80 01/06/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY PC
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200045
Principal investigator 1 Novartis Pharmaceuticals Corporation $707,976.73 01/01/2025 Non-covered Recipient Entity
JOSEPHSON WALLACK MUNSHOWER NEUROLOGY
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190307623